research Étude PCPT : les biais attendus et leur gestion
Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.
Measuring OPC-17116 in hair can reliably indicate drug exposure and timing.
research Psychiatric and sexual dysfunction warnings strengthened for finasteride and dutasteride
Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
research Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
Certain medications, especially nervous system drugs, can cause insomnia, with risks varying by age and gender.
research Preparatory work to support the risk assessment for peri‐ and postmenopausal women taking food supplements containing isolated isoflavones
Isoflavones may help with menopause symptoms but could be risky for women with hormone-sensitive cancers.
research Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies
The review concluded that reporting on PRP therapy is often incomplete, leading to uncertainty about its effectiveness.
research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
research Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients
Post-finasteride patients show changed neuroactive steroid levels, possibly causing erectile dysfunction and depression.
research Studies on the stability of finasteride sustained-release tablets
Finasteride sustained-release tablets are stable.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research The Evidence for Microbes in the Small Intestine as the Mechanism for Post-Finasteride Syndrome: Self-Reported Case Study
Microbes in the small intestine may cause Post-Finasteride Syndrome symptoms.
research Finasteride
Man experienced lasting sexual dysfunction from finasteride, but malpractice claim was rejected.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application
Improved finasteride formula allows slow, sustained release and better absorption for patients.
research PD20-08 INVESTIGATION OF SEXUAL DYSFUNCTION LINKED TO FINASTERIDE USE: A PHARMACOVIGILANCE ANALYSIS
Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
research Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis
Health warnings and public health actions led to a significant drop in flutamide prescriptions for women, but off-label use still continues.
research Stability Study of Finasteride: Stability-Indicating LC Method, In Silico and LC–ESI-MS Analysis of Major Degradation Product, and an In Vitro Biological Safety Study
Finasteride's stability and safety confirmed through precise analytical methods.
research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
In 1996, promoting drugs online was new and legally unclear.
research POPPER MACULOPATHY: LONG-TERM FOLLOW-UP AND CASE SERIES
Using poppers can cause vision problems, but stopping their use might lead to complete recovery over time.
research Reframing the Discussion on Finasteride and Neuropsychiatric Safety
Finasteride is not proven to cause depression or suicide, and careful patient monitoring is advised.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research 1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY
PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
research Peer Review #2 of "Computational drug repositioning based on side-effects mined from social media (v0.2)"
The peer review highlighted the need for clearer data handling, questioned the study's validity, and recognized improvements from the original version.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
research Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.3)"
Reviewers criticized the study's methods and suggested focusing on drug mechanisms instead of repositioning due to social media data quality concerns.
research Sunscreen: Cosmetic or medical therapy?
The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.
research Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults
Certain groups of medications given when leaving the hospital are linked to a higher risk of negative drug reactions within 30 days, especially in older adults with respiratory issues.
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.